Long-term Efficacy, Survival, and Toxicity of Peptide Receptor Radionuclide Therapy in Patients With Refractory Meningioma
PRRT showed promising outcomes in patients with refractory meningiomas, with high disease control and encouraging progression-free survival and OS, and therefore appears to be a favorable therapeutic option. With long-term follow-up, PRRT demonstrated a favorable safety profile, resulting in very few side effects in this cohort of patients with meningioma.
Authors
- Vivianne Jakobsson (ORCID: https://orcid.org/0009-0006-2087-0347)
- Richard P. Baum (ORCID: https://orcid.org/0000-0003-1723-0075)
- Jingjing Zhang (ORCID: https://orcid.org/0000-0002-6948-1813)
- H. R. Kulkarni (ORCID: https://orcid.org/0000-0002-8085-1096)
- Deling Li (ORCID: https://orcid.org/0000-0002-4300-7136)
- Wang Xiao Jia (ORCID: https://orcid.org/0000-0002-0992-6702)
- Mengqi Shi (ORCID: https://orcid.org/0000-0002-8379-5202)
- Christiane Schuchardt
Institutions
- National University of Singapore (SG)
- Capital Medical University (CN)
- Beijing Tian Tan Hospital (CN)
- Zentralklinik Bad Berka (DE)
Publication Details
- Journal
- Clinical Nuclear Medicine
- Published
- 2025-05-05
- DOI
- https://doi.org/10.1097/rlu.0000000000005845
- Citations
- 4
- Primary Topic
- Meningioma and schwannoma management
- Type
- article
- Field-Weighted Citation Impact
- 5.42